Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.59 USD | -0.62% | +0.63% | -19.29% |
04-29 | Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem | CI |
03-28 | Transcript : Iterum Therapeutics plc, Q4 2023 Earnings Call, Mar 28, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.29% | 26.49M | |
+24.95% | 46.71B | |
+48.83% | 41.8B | |
-1.09% | 41.52B | |
-5.86% | 29.55B | |
+10.66% | 25.78B | |
-20.47% | 19.26B | |
+1.54% | 12.14B | |
-3.18% | 12.08B | |
+27.34% | 11.98B |
- Stock Market
- Equities
- ITRM Stock
- News Iterum Therapeutics plc
- Iterum Therapeutics : Gabelli & Co Upgrades Iterum Therapeutics to Hold From Sell